Lymphoma

Latest News

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.
FDA Issues CRL for Tabelecleucel in EBV+ Lymphoproliferative Disease

January 17th 2025

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

Brentuximab Vedotin Combination Improves Survival in Pretreated R/R DLBCL
Brentuximab Vedotin Combination Improves Survival in Pretreated R/R DLBCL

January 17th 2025

FDA Approves Acalabrutinib Combo in Previously Untreated MCL
FDA Approves Acalabrutinib Combo in Previously Untreated MCL

January 16th 2025

Integrating Acalabrutinib Plus Bendamustine/Rituximab in the Frontline MCL Treatment Protocol
Integrating Acalabrutinib Plus Bendamustine/Rituximab in the Frontline MCL Treatment Protocol

December 31st 2024

3 Things You Should Know About Immunotherapy in DLBCL
3 Things You Should Know About Immunotherapy in DLBCL

December 19th 2024